Search
Search filters
Type
Audience
Category
Issue
Last updated
Recall class
Displaying 46 - 60 of 717 items.
Robikids and Solmux are unauthorized children’s syrups for thinning mucus and may pose serious health risks
AlertPublic advisory | 2023-03-16
Unauthorized health products from Kausch International Goods may pose serious health risks
AlertPublic advisory | 2023-03-01
Unauthorized prescription drug called Solmux removed from sale from Palengke Pinoy store in Camrose, AB, and Facebook store
AlertPublic advisory | 2023-02-17
Amitriptyline antidepressant drugs recalled because of a nitrosamine impurity
AlertPublic advisory | 2023-02-07
APO-AMITRIPTYLINE 10mg: NDMA Impurity
RecallHealth product recall | 2023-02-07
Know the risks: Replacing a healthy natural eye lens with an intraocular eye lens for vision correction
AlertPublic advisory | 2023-02-03
Unauthorized health products removed from sale from More to Shoppe Facebook store and its Edson, Alberta, warehouse
AlertPublic advisory | 2023-01-20
EVUSHELD (tixagevimab and cilgavimab for injection) - Risk of Prophylaxis or Treatment Failure due to Antiviral Resistance to specific SARS-CoV-2 Subvariants
AlertHealth professional risk communication | 2023-01-17
COMIRNATY Original & Omicron BA.4/BA.5 Bivalent Vaccine with English-only Vial and Carton Labels: New Formulation for Use in Children 5 to Less Than 12 Years of Age
AlertHealth professional risk communication | 2022-12-09
TUMS Peppermint Regular Strength tablets: One lot recalled due to contamination
AlertPublic advisory | 2022-11-30
SPIKEVAX Bivalent (Original / Omicron BA.4/5) (elasomeran/davesomeran) COVID-19 Vaccine with English-only Vial and Carton Labels
AlertHealth professional risk communication | 2022-11-18
Unlicensed ozone saunas may pose serious health risks to users and anyone in close proximity
AlertPublic advisory | 2022-11-02
Janus Kinase Inhibitors and the Risk of Major Adverse Cardiovascular Events, Thrombosis (Including Fatal Events) and Malignancy
AlertHealth professional risk communication | 2022-10-31
EVUSHELD (tixagevimab and cilgavimab for injection) - Risk of Prophylaxis or Treatment Failure due to Antiviral Resistance
AlertHealth professional risk communication | 2022-10-26